LACTOLOGY FOUNDATION

Betaine Hydrochloride (ATC A09AB02): Toxicological and Lactological Monograph

ATC class and general pharmacology

ATC code A09AB02 corresponds to betaine hydrochloride, classified within the Anatomical Therapeutic Chemical system as an acid preparation used in disorders of gastric acid secretion. Betaine hydrochloride is the hydrochloride salt of betaine (trimethylglycine), a naturally occurring quaternary ammonium compound found in foods such as beetroot, spinach, wheat products, and seafood. It may also be formed endogenously from choline metabolism.

In digestive preparations, betaine hydrochloride is used to acidify gastric contents and has historically been administered as a source of hydrochloric acid in suspected hypochlorhydria or achlorhydria. This use should be distinguished from prescription anhydrous betaine, which is a methyl-group donor indicated for homocystinuria. Although both forms yield betaine after absorption, they have different ATC contexts, clinical purposes, doses, and risk considerations. The ATC A09AB02 designation specifically concerns the hydrochloride salt used as a gastric-acid preparation.genome

After oral administration, betaine hydrochloride dissociates in the gastrointestinal tract, contributing hydrochloride ions and releasing betaine. The acidifying effect is expected to occur locally within the stomach. The absorbed betaine moiety functions as an organic osmolyte and methyl donor. In hepatic metabolism, betaine can donate a methyl group during the betaine–homocysteine methyltransferase reaction, facilitating remethylation of homocysteine to methionine and generating dimethylglycine. This biochemical role is the basis for the therapeutic use of high-dose anhydrous betaine in homocystinuria.dailymed.nlm.nih+1

The clinical role of supplemental gastric acid remains limited and should not replace investigation of persistent dyspepsia, iron or vitamin B12 deficiency, unexplained weight loss, gastrointestinal bleeding, anemia, recurrent vomiting, dysphagia, or suspected malabsorption. These features warrant medical assessment rather than empiric self-treatment with acidifying agents.

Toxicological profile

The toxicological profile of betaine hydrochloride depends substantially on dose, formulation, coexisting disease, and whether the principal exposure is low-dose digestive supplementation or high-dose systemic betaine therapy. At customary oral supplemental doses, adverse effects are mainly gastrointestinal and may include nausea, epigastric discomfort, abdominal pain, heartburn, dyspepsia, diarrhea, and gastric irritation. Nausea and general gastrointestinal upset are also described with orally administered betaine products.mayoclinic+1

The hydrochloride component can aggravate conditions in which gastric or esophageal mucosa is vulnerable to acid injury. Betaine hydrochloride should therefore be avoided or used only with specialist advice in individuals with active peptic ulcer disease, erosive gastritis, gastroesophageal reflux disease with significant esophagitis, Barrett’s esophagus, prior upper-gastrointestinal bleeding, or concurrent use of medicines that increase the risk of mucosal injury. Particular caution is appropriate with non-steroidal anti-inflammatory drugs, systemic corticosteroids, antiplatelet drugs, and anticoagulants when there is an underlying risk of ulceration or bleeding.

Systemic toxicological concerns are more clearly documented with pharmacological doses of anhydrous betaine used for homocystinuria. By promoting remethylation of homocysteine to methionine, high-dose betaine can increase plasma methionine concentrations. In patients with cystathionine beta-synthase deficiency, marked hypermethioninemia has been associated with cerebral edema. Product information advises monitoring plasma methionine and maintaining concentrations below 1,000 micromol/L through dietary management and, if needed, dose reduction. Serious cases occurred within approximately two weeks to six months after initiation of treatment and improved after discontinuation.fda+1

This severe reaction is not expected from ordinary digestive doses of betaine hydrochloride in otherwise healthy people. Nevertheless, it illustrates that “natural” or nutrient-related compounds may have clinically important metabolic effects at high doses or in susceptible patients. Patients with homocystinuria, inherited methionine-pathway disorders, liver disease, renal impairment, or unexplained elevations in methionine or homocysteine should not self-administer large amounts of betaine-containing products.

Lactation pharmacology and infant exposure

Betaine is a naturally occurring constituent of human physiology and is relevant to one-carbon metabolism, cellular osmoregulation, choline metabolism, and methyl-group transfer. It is also present in foods regularly consumed by lactating women. However, the natural presence of betaine in the maternal diet or in human milk does not automatically establish the safety of concentrated pharmaceutical or supplement formulations during breastfeeding.

Direct, high-quality pharmacokinetic evidence for betaine hydrochloride at A09AB02 digestive doses in lactating women is insufficient. In particular, there are no robust published data establishing the milk-to-plasma ratio, time course of milk concentrations after a specific oral betaine hydrochloride dose, relative infant dose, infant serum concentrations, or clinical outcomes in breastfed infants exposed through milk.

Available evidence suggests that maternal dietary factors can influence milk betaine content. A human observation cited in experimental work found that choline supplementation during lactation increased maternal plasma and milk betaine concentrations. Animal data also show that increased maternal betaine intake can raise betaine concentrations in milk. These findings support biological plausibility for transfer into milk, but they do not quantify infant exposure after therapeutic use of betaine hydrochloride and cannot establish clinical safety in human infants.pmc.ncbi.nlm.nih+1

For prescription anhydrous betaine, labeling states that data are lacking on its presence in human or animal milk, effects on the breastfed infant, and effects on milk production. Earlier product information similarly noted that it was unknown whether Cystadane was excreted in human milk. This evidence gap is especially relevant because prescription treatment for homocystinuria commonly involves gram-level doses, which are substantially different from the exposures expected from ordinary food intake or low-dose digestive supplements.fda+1

Infant exposure after maternal use of betaine hydrochloride is therefore expected to be influenced by:

• Maternal dose, frequency, formulation, and timing relative to feeds.
• Maternal gastrointestinal absorption and systemic betaine availability.
• The infant’s age, body weight, hepatic and renal function, and clinical stability.
• Whether the infant is preterm, medically fragile, or affected by an inherited metabolic disorder.
• Co-exposure to other medicines or supplements used by the mother.

The hydrochloride ion itself is not expected to create a clinically meaningful independent acidification of breast milk or of the infant’s systemic circulation at usual maternal oral doses, because body acid–base homeostasis tightly regulates chloride handling. The principal theoretical infant exposure of interest is the absorbed betaine moiety rather than a direct “hydrochloric acid” effect in milk.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: betaïne hydrochloride should be considered a substance with insufficient direct human lactation data, rather than one that is proven incompatible with breastfeeding. Low-dose, short-term maternal use for a clearly justified digestive indication is unlikely to create substantial systemic infant toxicity in a healthy term infant, but this conclusion is based on pharmacological reasoning and the endogenous/nutritional nature of betaine—not on adequate studies of breastfed infants exposed to A09AB02 products.

The lack of direct milk-concentration and infant-outcome data means that routine, prolonged, or high-dose use during lactation should not be encouraged without clinical review. This is particularly important because self-diagnosed “low stomach acid” is not a reliable diagnosis, while acidifying products may worsen reflux disease, gastritis, or peptic ulceration in the mother.

Practical recommendations

• Use betaine hydrochloride during breastfeeding only when there is a clear indication and when non-pharmacological or better-studied alternatives are unsuitable.
• Prefer the lowest effective dose for the shortest clinically necessary duration.
• Avoid unsupervised use in mothers with peptic ulcer disease, erosive gastritis, significant reflux esophagitis, upper-gastrointestinal bleeding, or persistent unexplained dyspeptic symptoms.
• Do not extrapolate safety from food-derived betaine to gram-level anhydrous betaine therapy for homocystinuria.
• Women receiving high-dose betaine for homocystinuria require specialist metabolic management, including methionine monitoring where clinically indicated; breastfeeding decisions should be individualized with a metabolic physician and lactation-informed clinician.fda+1
• In a healthy, full-term infant, routine interruption of breastfeeding is not automatically required after occasional low-dose maternal exposure, but clinical judgment remains necessary because direct lactation evidence is lacking.
• Consider closer observation or specialist consultation if the infant is premature, has low birth weight, has hepatic or renal disease, has feeding difficulties, or is suspected to have an inborn error of metabolism.
• Monitor the infant for unusual gastrointestinal symptoms such as persistent vomiting, diarrhea, marked irritability, poor feeding, or inadequate weight gain. These effects are nonspecific and do not prove causation, but they justify pediatric assessment if persistent.
• Investigate maternal alarm symptoms—dysphagia, gastrointestinal bleeding, anemia, weight loss, recurrent vomiting, severe pain, or persistent dyspepsia—rather than treating repeatedly with acidifying supplements.

Clinical interpretation

For a lactating patient using a standard digestive betaine hydrochloride preparation intermittently, the main clinical issue may be maternal gastrointestinal safety more than proven infant toxicity. By contrast, for a patient prescribed high-dose anhydrous betaine for homocystinuria, the maternal metabolic disease, therapeutic dose, plasma methionine concentration, co-treatment, and infant vulnerability become central to lactation counseling.

Accordingly, betaine hydrochloride is best categorized as a lactation exposure with a plausible low risk at limited digestive doses in healthy mother–infant dyads, but with low certainty of evidence. It should not be regarded as an evidence-established lactation-compatible medicine, and individualized professional assessment is appropriate when treatment is ongoing, high-dose, medically complex, or directed at a metabolic disorder.fda+1